Crossmark

Real-World Treatment Switch Rates, and Healthcare Costs of Botulinum Toxin Type A Among Patients with Cervical Dystonia in the USA: A Retrospective Claims Analysis

Crossref DOI link: https://doi.org/10.1007/s40120-026-00967-3

Published Online: 2026-06-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cheng, Ning

Dominguez, Annaliza

Manthena, Shivaji R.

Shah, Darshini
Funding

Funding for this research was provided by:

AbbVie
License Information

Text and Data Mining valid from 2026-06-05

Version of Record valid from 2026-06-05
More Information

Article History

Received: 13 February 2026

Accepted: 13 May 2026

First Online: 5 June 2026

Declarations

:

: Ning Cheng, Annaliza Dominguez, and Shivaji R Manthena, are employees of AbbVie and may hold AbbVie stock. Darshini Shah is a former employee of AbbVie and may hold AbbVie stock. She is no longer employed by AbbVie. She is an employee of Axsome Therapeutics Inc., New York, NY, USA and may hold Axsome Therapeutics Inc. stock.

: The article does not contain any new studies with human participants or animals performed by any of the authors.

Document is current

Any future updates will be listed below